Armata Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ARMP NYSE American 2836 www.armatapharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia - May 19th, 2025 5:00 am
Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update - May 14th, 2025 2:05 pm
Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 - May 1st, 2025 5:00 am
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update - Mar 20th, 2025 3:56 pm
Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva - Mar 12th, 2025 3:08 pm
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit - Mar 11th, 2025 5:00 am
Armata Pharma’s inhaled AP-PA02 shows positive results in Phase 2 study - Dec 20th, 2024 5:15 am
Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection - Dec 19th, 2024 5:00 am
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting - Nov 19th, 2024 5:00 am
Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update - Nov 13th, 2024 2:05 pm
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia - Nov 12th, 2024 5:00 am
Armata Pharmaceuticals Announces Structural Biology Publication - Oct 30th, 2024 5:00 am
Armata Pharmaceuticals (ARMP) Upgraded to Buy: What Does It Mean for the Stock? - Sep 12th, 2024 10:00 am
Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Sep 5th, 2024 5:30 am
Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium - Aug 26th, 2024 5:30 am
Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer - Aug 15th, 2024 2:45 pm
Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update - Aug 13th, 2024 2:05 pm
Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 - Jul 30th, 2024 5:00 am
Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection - Jul 11th, 2024 5:00 am
Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024 - Jul 10th, 2024 2:05 pm